<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.1 20050630//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Biol</journal-id><journal-id journal-id-type="publisher-id">pbio</journal-id><journal-title>PLoS Biology</journal-title><issn pub-type="ppub">1544-9173</issn><issn pub-type="epub">1545-7885</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1371/journal.pbio.0000083</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Cancer Biology</subject><subject>Cell Biology</subject><subject>Molecular Biology/Structural Biology</subject></subj-group><subj-group subj-group-type="System Taxonomy"><subject>Mus (Mouse)</subject></subj-group></article-categories><title-group><article-title>Inhibition of HIF2&#x003b1; Is Sufficient to Suppress pVHL-Defective Tumor Growth</article-title><alt-title alt-title-type="running-head">HIF2&#x003b1; Required by pVHL-Defective Tumors</alt-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name><surname>Kondo</surname><given-names>Keiichi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name><surname>Kim</surname><given-names>William Y</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name><surname>Lechpammer</surname><given-names>Mirna</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple" corresp="yes"><name><surname>Kaelin</surname><given-names>William G</given-names><suffix>Jr</suffix></name><email>william&#x0005f;kaelin&#x00040;dfci.harvard.edu</email><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff1"><bold>1</bold><institution>Department of Adult Oncology, Dana&#x02013;Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School</institution><addr-line>Boston, Massachusetts</addr-line><country>United States of America</country></aff><aff id="aff2"><bold>2</bold><institution>Department of Pathology, Dana&#x02013;Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School</institution><addr-line>Boston, Massachusetts</addr-line><country>United States of America</country></aff><aff id="aff3"><bold>3</bold><institution>Howard Hughes Medical Institute</institution><addr-line>Chevy Chase, Maryland</addr-line><country>United States of America</country></aff><pub-date pub-type="ppub"><month>12</month><year>2003</year></pub-date><pub-date pub-type="epub"><day>22</day><month>12</month><year>2003</year></pub-date><volume>1</volume><issue>3</issue><elocation-id>e83</elocation-id><history><date date-type="received"><day>15</day><month>9</month><year>2003</year></date><date date-type="accepted"><day>21</day><month>10</month><year>2003</year></date></history><copyright-statement>Copyright: &#x000a9; 2003 Kondo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited</copyright-statement><copyright-year>2003</copyright-year><related-article xlink:href="10.1371/journal.pbio.0000090" related-article-type="companion" xlink:title="synopsis" vol="1" page="e90" id="N0x8b555a0.0x975d04c" ext-link-type="doi"><article-title>Inhibition of HIF2&#x003b1; Protein Suppresses pVHL-Driven Tumor Growth</article-title></related-article><abstract><p>Biallelic inactivation of the von Hippel&#x02013;Lindau tumor suppressor gene (<italic>VHL</italic>) is linked to the development of hereditary (VHL-associated) and sporadic clear-cell renal carcinomas as well as other abnormalities. The <italic>VHL</italic> gene product, pVHL, is part of an E3 ubiquitin ligase complex that targets the &#x003b1; subunits of the heterodimeric transcription factor HIF (hypoxia-inducible factor) for degradation in the presence of oxygen. Here we report that a HIF2&#x003b1; variant lacking both of its two prolyl hydroxylation/pVHL-binding sites prevents tumor inhibition by pVHL in a DNA-binding dependent manner. Conversely, downregulation of HIF2&#x003b1; with short hairpin RNAs is sufficient to suppress tumor formation by pVHL-defective renal carcinoma cells. These results establish that tumor suppression by pVHL is linked to regulation of HIF target genes.</p></abstract><abstract abstract-type="toc"><p>Specific downregulation of the transcription factor HIF2&#x003b1; is sufficient to suppress tumor formation by cells lacking the functional tumor suppressor (pVHL), demonstrating that tumor suppression by pVHL is linked to regulation of HIF target genes</p></abstract></article-meta></front><body><sec id="s1"><title>Introduction</title><p>von Hippel&#x02013;Lindau (VHL) disease is caused by heterozygous germline inactivation of the <italic>VHL</italic> tumor suppressor gene, which resides on chromosome 3p25 (<xref ref-type="bibr" rid="pbio.0000083-Kaelin1">Kaelin 2002</xref>). The cardinal feature of this hereditary cancer syndrome is the development of multiple vascular tumors, called hemangioblastomas, in the central nervous system and retina, as well as an increased risk of clear-cell carcinoma of the kidney and pheochromocytoma. Tumor development in VHL disease is linked to somatic inactivation or loss of the remaining wild-type <italic>VHL</italic> allele, leading to loss of the wild-type <italic>VHL</italic> gene product, pVHL. In the kidney, this event occurs very early, as it has been documented in epithelial cells lining premalignant renal cysts (<xref ref-type="bibr" rid="pbio.0000083-Zhuang1">Zhuang et al. 1995</xref>; <xref ref-type="bibr" rid="pbio.0000083-Lubensky1">Lubensky et al. 1996</xref>; <xref ref-type="bibr" rid="pbio.0000083-Mandriota1">Mandriota et al. 2002</xref>). Consistent with Knudson's two-hit model, somatic <italic>VHL</italic> mutations are also common in sporadic clear-cell renal carcinomas and hemangioblastomas. Conversely, restoration of pVHL function is sufficient to suppress tumor formation by pVHL-defective renal carcinoma cells in vivo (<xref ref-type="bibr" rid="pbio.0000083-Iliopoulos1">Iliopoulos et al. 1995</xref>; <xref ref-type="bibr" rid="pbio.0000083-Gnarra2">Gnarra et al. 1996</xref>; <xref ref-type="bibr" rid="pbio.0000083-Schoenfeld1">Schoenfeld et al. 1998</xref>).</p><p>pVHL is the substrate recognition module of an E3 ubiquitin ligase complex that contains elongin B, elongin C, Cul2, and Rbx1 (also called ROC1 or Hrt1) (<xref ref-type="bibr" rid="pbio.0000083-Kaelin1">Kaelin 2002</xref>). This complex targets the &#x003b1; subunits of the heterodimeric transcription factor HIF (hypoxia-inducible factor) for polyubiquitination and hence proteasomal degradation. There are three human HIF&#x003b1;<bold/>proteins (HIF1&#x003b1;, HIF2&#x003b1;, and HIF3&#x003b1;). Enzymatic hydroxylation of conserved prolyl residues within these proteins by members of the egg-laying-defective nine (EGLN) family is required for their recognition by pVHL (<xref ref-type="bibr" rid="pbio.0000083-Kaelin1">Kaelin 2002</xref>). This posttranslational modification is inherently oxygen-dependent. Accordingly, HIF&#x003b1; subunits are normally unstable in the presence of oxygen, but are stabilized under low-oxygen (hypoxic) conditions. In contrast, cells lacking wild-type pVHL fail to degrade HIF&#x003b1; subunits in the presence of oxygen, and thus hypoxia-inducible gene products are constitutively overproduced. Among these proteins are vascular endothelial growth factor (VEGF) and platelet-derived growth factor B, implicated in angiogenesis; phosphoglycerate kinase and glucose transporter 1 (GLUT1), involved in glucose uptake and metabolism; and transforming growth factor &#x003b1; (TGF&#x003b1;), which can establish a mitogenic autocrine loop with the epidermal growth factor (EGF) receptor (EGFR) (<xref ref-type="bibr" rid="pbio.0000083-Iliopoulos2">Iliopoulos et al. 1996</xref>; <xref ref-type="bibr" rid="pbio.0000083-Knebelmann1">Knebelmann et al. 1998</xref>; <xref ref-type="bibr" rid="pbio.0000083-Maxwell2">Maxwell et al. 1999</xref>; <xref ref-type="bibr" rid="pbio.0000083-de1">de Paulsen et al. 2001</xref>).</p><p>Tumor-derived pVHL mutants are typically defective with respect to HIF polyubiquitination in vivo, and the HIF target genes cited above are implicated in tumorigenesis. Thus, correlative data and biological plausibility support a role for HIF in pVHL-defective tumor formation. Nonetheless, emerging genotype&#x02013;phenotype correlations in VHL disease suggest that pVHL has multiple functions. For example, pVHL mutants associated with a low risk (type 2A VHL disease) and high risk (type 2B disease) of renal cell carcinoma are similarly defective with respect to HIF regulation (<xref ref-type="bibr" rid="pbio.0000083-Clifford1">Clifford et al. 2001</xref>; <xref ref-type="bibr" rid="pbio.0000083-Hoffman1">Hoffman et al. 2001</xref>). Interestingly, individuals with Chuvash polycythemia are homozygous for a hypomorphic <italic>VHL</italic> allele that is quantitatively defective with respect to HIF regulation, which leads to overproduction of erythropoietin in vivo but not tumor formation (<xref ref-type="bibr" rid="pbio.0000083-Ang1">Ang et al. 2002</xref>). Moreover, forced activation of HIF target genes has not led to tumor formation in the animal models tested so far (<xref ref-type="bibr" rid="pbio.0000083-Vincent1">Vincent et al. 2000</xref>; <xref ref-type="bibr" rid="pbio.0000083-Elson1">Elson et al. 2001</xref>; <xref ref-type="bibr" rid="pbio.0000083-Rebar1">Rebar et al. 2002</xref>). Conversely, some pVHL mutants that retain the ability to regulate HIF are linked to familial pheochromocytoma (type 2C VHL disease) (<xref ref-type="bibr" rid="pbio.0000083-Clifford1">Clifford et al. 2001</xref>; <xref ref-type="bibr" rid="pbio.0000083-Hoffman1">Hoffman et al. 2001</xref>). Collectively, these findings suggest that tumor formation following pVHL inactivation reflects the loss of multiple pVHL functions in a context-dependent manner.</p><p>In this report we provide data that strengthen our earlier conclusion that inhibition of HIF2&#x003b1; is necessary for pVHL-dependent suppression of renal carcinoma tumor formation in vivo (<xref ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>). Moreover, we provide evidence that inhibition of HIF2&#x003b1; is likewise sufficient to suppress tumor formation by <italic>VHL</italic>(&#x02212;/&#x02212;) renal carcinoma cells in vivo. Collectively, these results indicate that HIF2&#x003b1; is a critical downstream target of pVHL with respect to suppression of renal carcinogenesis.</p></sec><sec id="s2"><title>Results and Discussion</title><sec id="s2a"><title>Inhibition of HIF2&#x003b1; Target Genes Is Necessary for Tumor Suppression by pVHL</title><p>Hydroxylation of HIF1&#x003b1; Pro564 or HIF2&#x003b1; Pro531 generates a pVHL-binding site (<xref ref-type="bibr" rid="pbio.0000083-Ivan1">Ivan et al. 2001</xref>; <xref ref-type="bibr" rid="pbio.0000083-Jaakkola1">Jaakkola et al. 2001</xref>; <xref ref-type="bibr" rid="pbio.0000083-Yu1">Yu et al. 2001</xref>). We previously showed that a HIF2&#x003b1; variant in which Pro531 was replaced by alanine (HIF2&#x003b1; P531A) escaped recognition by pVHL and induced the expression of HIF target genes in vivo (<xref ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>). Moreover, HIF2&#x003b1; P531A abrogated pVHL-dependent tumor suppression in vivo, implying that HIF is functionally downstream of pVHL and that inhibition of HIF is necessary for tumor suppression by pVHL (<xref ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>). Shortly thereafter, it was shown that hydroxylation of HIF1&#x003b1; Pro404 (corresponding to HIF2&#x003b1; Pro405) creates a second potential pVHL-binding site within HIF1&#x003b1; (<xref ref-type="bibr" rid="pbio.0000083-Masson1">Masson et al. 2001</xref>). Although we could not detect a physical interaction between pVHL and HIF2&#x003b1; P531A (<xref ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>), the identification of a second potential pVHL-binding site left open the possibility that the biological effects of HIF2&#x003b1; P531A were due, at least partly, to perturbation of pVHL function as a result of direct binding. If true, this would undermine the conclusions described above. Moreover, we had not established whether the biological effects of HIF2&#x003b1; P531A required that it bind to DNA, as would be expected if its oncogenic effects were due to transcriptional activation of specific hypoxia-inducible promoters. To this end, we repeated our earlier experiments using retroviral vectors encoding HIF2&#x003b1; P405A;P531A or HIF2&#x003b1; P405A;P531A;bHLH&#x0002a;. The latter contains a five amino acid substitution within the HIF2&#x003b1; basic helix&#x02013;loop&#x02013;helix (bHLH) domain that leads to loss of DNA-binding capability (<xref ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>).</p><p>786-O renal carcinoma cells lack wild-type pVHL and overproduce HIF2&#x003b1; (<xref ref-type="bibr" rid="pbio.0000083-Iliopoulos1">Iliopoulos et al. 1995</xref>; <xref ref-type="bibr" rid="pbio.0000083-Maxwell2">Maxwell et al. 1999</xref>). HIF1&#x003b1; is not detectable in these cells (<xref ref-type="bibr" rid="pbio.0000083-Maxwell2">Maxwell et al. 1999</xref>). Reintroduction of wild-type pVHL into 786-O cells by stable transfection does not affect cell growth in vitro under standard serum-rich growth conditions, but leads to downregulation of HIF2&#x003b1; protein levels, suppression of hypoxia-inducible gene expression, and impaired tumorigenesis in vivo (<xref ref-type="bibr" rid="pbio.0000083-Iliopoulos1">Iliopoulos et al. 1995</xref>, <xref ref-type="bibr" rid="pbio.0000083-Iliopoulos2">1996</xref>; <xref ref-type="bibr" rid="pbio.0000083-Gnarra2">Gnarra et al. 1996</xref>; <xref ref-type="bibr" rid="pbio.0000083-Schoenfeld1">Schoenfeld et al. 1998</xref>; <xref ref-type="bibr" rid="pbio.0000083-Maxwell2">Maxwell et al. 1999</xref>; <xref ref-type="bibr" rid="pbio.0000083-Davidowitz1">Davidowitz et al. 2001</xref>). A 786-O subclone stably transfected to produce wild-type pVHL (WT8) (<xref ref-type="bibr" rid="pbio.0000083-Iliopoulos1">Iliopoulos et al. 1995</xref>) was infected with a retrovirus encoding HIF2&#x003b1; P405A;P531A or HIF2&#x003b1; P405A;P531A;bHLH&#x0002a; and grown under hypoxic (1&#x00025; oxygen) or normoxic (21&#x00025; oxygen) conditions. As expected, HIF2&#x003b1; was only detectable under hypoxic conditions in WT8 cells and in WT8 cells infected with an empty retrovirus (<xref ref-type="fig" rid="pbio.0000083-g001">Figure 1</xref>A). In contrast, HIF2&#x003b1; was readily detectable under both hypoxic and normoxic conditions in WT8 cells infected to produce either of the two HIF2&#x003b1; P405A;P531A variants. Indeed, the levels of HIF2&#x003b1; present in these cells approximated those seen in a 786-O subclone (PRC3) (<xref ref-type="bibr" rid="pbio.0000083-Iliopoulos1">Iliopoulos et al. 1995</xref>) that, unlike WT8 cells, was stably transfected with an empty expression plasmid and hence still lacks wild-type pVHL.</p><p>Neither HIF2&#x003b1; P405A;P531A nor HIF2&#x003b1; P405A;P531A;bHLH&#x0002a; affected the proliferation of WT8 cells in vitro under standard cell culture conditions (<xref ref-type="fig" rid="pbio.0000083-g001">Figure 1</xref>B). In contrast, but in keeping with our earlier results with HIF2&#x003b1; P531A (<xref ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>), HIF2&#x003b1; P405A;P531A restored the ability of WT8 cells to form large tumors in vivo in <italic>nude</italic> mouse xenograft assays (<xref ref-type="fig" rid="pbio.0000083-g001">Figure 1</xref>C). HIF2&#x003b1; P405A;P531A;bHLH&#x0002a; did not promote tumor formation by WT8 cells, implying that tumor promotion by HIF2&#x003b1; P405A;P531A is linked to its ability to act as a sequence-specific DNA-binding transcriptional regulator. These results, together with our earlier findings, indicate that inhibition of HIF2&#x003b1; is necessary for tumor suppression by pVHL.</p></sec><sec id="s2b"><title>Loss of HIF2&#x003b1; Is Sufficient to Suppress pVHL-Defective Tumor Growth In Vivo</title><p>To ask whether inhibition of HIF2&#x003b1; is likewise sufficient for tumor suppression by pVHL, we set out to inhibit HIF2&#x003b1; in <italic>VHL</italic>(&#x02212;/&#x02212;) renal carcinoma cells using short hairpin RNAs (shRNA). We tested five HIF2&#x003b1; shRNAs based on 19mer sequences that are unique to HIF2&#x003b1; according to GenBank. Two such shRNAs (#2 and #3) decreased HIF2&#x003b1; protein levels, as determined by anti-HIF2&#x003b1; immunoblot analysis and by diminished activity of a cotransfected HRE&#x02013;luciferase reporter plasmid, when transiently introduced into 786-O cells (data not shown). Infection of 786-O cells with retroviruses encoding shRNA #2 or #3, but not the parental retrovirus, led to decreased steady-state levels of HIF2&#x003b1; protein as well as decreased levels of GLUT1, which is encoded by a HIF-responsive gene (<xref ref-type="fig" rid="pbio.0000083-g002">Figure 2</xref>A). Downregulation of HIF2&#x003b1; did not affect cell growth in vitro, but was sufficient to impair tumor growth in vivo (<xref ref-type="fig" rid="pbio.0000083-g002">Figure 2</xref>B&#x02013;<xref ref-type="fig" rid="pbio.0000083-g002">2</xref>D). The former observation is consistent with the finding that pVHL does not inhibit cell proliferation under standard cell culture conditions and argues against the idea that the latter was due to nonspecific toxicity. Moreover, these in vivo effects could be prevented by coadministration of a retrovirus encoding an HIF2&#x003b1; mRNA with silent third-base mutations within the shRNA recognition site (<xref ref-type="fig" rid="pbio.0000083-g003">Figure 3</xref>) and were not observed with retroviruses encoding a scrambled HIF2&#x003b1; shRNA or luciferase shRNA (data not shown). Thus, tumor suppression by the HIF2&#x003b1; shRNA was unlikely to reflect a spurious interaction with an unintended target.</p><p>To ask whether these findings could be extended to other <italic>VHL</italic>(&#x02212;/&#x02212;) renal carcinoma cell lines, we repeated these experiments in A498 <italic>VHL</italic>(&#x02212;/&#x02212;) renal carcinoma cells. Tumor formation by these cells in <italic>nude</italic> mice is diminished following restoration of pVHL function (<xref ref-type="bibr" rid="pbio.0000083-Lonergan1">Lonergan et al. 1998</xref>). In keeping with the results obtained with 786-O cells, downmodulation of HIF2&#x003b1; levels with shRNA did not affect A498 cell growth in vitro (data not shown), but dramatically inhibited tumor growth in vivo (<xref ref-type="fig" rid="pbio.0000083-g004">Figure 4</xref>A). It is noteworthy that both 786-O cells and A498 cells produce HIF2&#x003b1; and not HIF1&#x003b1; (<xref ref-type="bibr" rid="pbio.0000083-Maxwell2">Maxwell et al. 1999</xref>). It will be important in the future to ask whether disruption of HIF2&#x003b1; is sufficient to suppress tumor formation by pVHL-defective cells that produce both HIF&#x003b1; paralogs. In this regard, studies of renal precursor lesions in VHL patients suggest that HIF2&#x003b1; is more oncogenic than HIF1&#x003b1; (<xref ref-type="bibr" rid="pbio.0000083-Mandriota1">Mandriota et al. 2002</xref>). It is tempting to speculate that loss of HIF1&#x003b1; expression in some pVHL-defective renal carcinoma cells confers a selective advantage in vivo, perhaps related to the ability of HIF1&#x003b1; to induce apoptosis in some settings (<xref ref-type="bibr" rid="pbio.0000083-Carmeliet1">Carmeliet et al. 1998</xref>).</p><p>Several histological renal carcinoma variants have been recognized, including clear-cell carcinoma and papillary (chromophil) carcinoma. <italic>VHL</italic> mutations are common in the former, but not in the latter (<xref ref-type="bibr" rid="pbio.0000083-Gnarra1">Gnarra et al. 1994</xref>; <xref ref-type="bibr" rid="pbio.0000083-Takahashi2">Takahashi et al. 2002</xref>). Interestingly, the small A498 tumors that did form in the presence of HIF2&#x003b1; shRNA consisted of malignant cells forming tubulopapillary structures, corresponding to papillary (chromophil) renal carcinoma histology, whereas the empty vector tumors consisted primarily of sheets of clear cells, as would be seen in typical clear-cell renal carcinoma, with interspersed areas displaying papillary features (<xref ref-type="fig" rid="pbio.0000083-g004">Figure 4</xref>B). This suggests that dysregulation of HIF2&#x003b1; is causally linked to the clear-cell pattern and is consistent with the tight linkage between <italic>VHL</italic> mutations and this renal carcinoma subtype.</p><p>Most of the work performed so far with respect to the oncogenic effects of HIF has focused exclusively on HIF1&#x003b1;, where both prooncogenic and antioncogenic effects have been reported (<xref ref-type="bibr" rid="pbio.0000083-Maxwell1">Maxwell et al. 1997</xref>; <xref ref-type="bibr" rid="pbio.0000083-Carmeliet1">Carmeliet et al. 1998</xref>; <xref ref-type="bibr" rid="pbio.0000083-Ryan1">Ryan et al. 1998</xref>, <xref ref-type="bibr" rid="pbio.0000083-Ryan2">2000</xref>; <xref ref-type="bibr" rid="pbio.0000083-Hopfl1">Hopfl et al. 2002</xref>). Likewise, loss of pVHL is prooncogenic in a restricted subset of human tissues (<xref ref-type="bibr" rid="pbio.0000083-Kaelin1">Kaelin 2002</xref>). In the mouse, loss of pVHL promotes hemangioma development in the liver, but inhibits tumor formation by embryonic stem cells (<xref ref-type="bibr" rid="pbio.0000083-Haase1">Haase et al. 2001</xref>; <xref ref-type="bibr" rid="pbio.0000083-Mack1">Mack et al. 2003</xref>). These observations conform to the emerging paradigm that the same mutation can be either prooncogenic or antioncogenic, depending on the molecular and cellular context. Therefore, one must be cautious in extrapolating our findings beyond human clear-cell renal carcinomas.</p><p>Loss of pVHL in the human kidney gives rise to premaligant renal cysts (<xref ref-type="bibr" rid="pbio.0000083-Zhuang1">Zhuang et al. 1995</xref>; <xref ref-type="bibr" rid="pbio.0000083-Lubensky1">Lubensky et al. 1996</xref>; <xref ref-type="bibr" rid="pbio.0000083-Mandriota1">Mandriota et al. 2002</xref>). It is presumed that additional mutations at non-<italic>VHL</italic> loci are required for conversion to frank renal cell carcinomas. It will therefore be of interest to determine whether dysregulation of HIF is sufficient to produce renal cysts. In this regard, TGF&#x003b1;, which is encoded by a HIF target gene, is a potent renal mitogen and is sufficient to induce renal cysts in the mouse (<xref ref-type="bibr" rid="pbio.0000083-Lowden1">Lowden et al. 1994</xref>; <xref ref-type="bibr" rid="pbio.0000083-Chailler1">Chailler and Briere 1998</xref>; <xref ref-type="bibr" rid="pbio.0000083-Ramp2">Ramp et al. 2000</xref>; <xref ref-type="bibr" rid="pbio.0000083-de1">de Paulsen et al. 2001</xref>). On the other hand, our data do not exclude the possibility that the development of renal pathology following pVHL loss in humans reflects a complex interplay between dysregulated HIF2&#x003b1; and loss of a second pVHL function. pVHL has been implicated in control of cell-cycle, differentiation, and extracellular matrix formation, although the extent to which these activities are due to control of HIF is not known (<xref ref-type="bibr" rid="pbio.0000083-Kaelin1">Kaelin 2002</xref>). A number of non-HIF pVHL-binding partners have, however, been reported, including atypical protein kinase C members, VDU1, SP1, and fibronectin (<xref ref-type="bibr" rid="pbio.0000083-Kaelin1">Kaelin 2002</xref>).</p></sec><sec id="s2c"><title>Therapeutic Implications</title><p>Our findings strengthen the notion that inhibition of HIF2&#x003b1; might be therapeutically useful in pVHL-defective clear-cell renal carcinoma. On the other hand, sequence-specific DNA-binding transcription factors have not proven to be attractive drug targets to date. For this reason, it will be important to determine which HIF2&#x003b1; target genes are necessary for its oncogenic activity. Among the known HIF targets, the abovementioned TGF&#x003b1; and its cognate receptor, EGFR, are frequently overproduced in renal carcinoma and are suspected to establish an autocrine loop (<xref ref-type="bibr" rid="pbio.0000083-Mydlo1">Mydlo et al. 1989</xref>; <xref ref-type="bibr" rid="pbio.0000083-Lager1">Lager et al. 1994</xref>; <xref ref-type="bibr" rid="pbio.0000083-Knebelmann1">Knebelmann et al. 1998</xref>; <xref ref-type="bibr" rid="pbio.0000083-de1">de Paulsen et al. 2001</xref>). A number of EGFR are presently in clinical trials (<xref ref-type="bibr" rid="pbio.0000083-Fabbro1">Fabbro et al. 2002</xref>). Likewise, overproduction of VEGF is common in renal cell carcinoma and likely contributes to tumor angiogenesis in this setting (<xref ref-type="bibr" rid="pbio.0000083-Walke1">Walke et al. 1991</xref>; <xref ref-type="bibr" rid="pbio.0000083-Brown1">Brown et al. 1993</xref>; <xref ref-type="bibr" rid="pbio.0000083-Takahashi1">Takahashi et al. 1994</xref>; <xref ref-type="bibr" rid="pbio.0000083-Nicol1">Nicol et al. 1997</xref>; <xref ref-type="bibr" rid="pbio.0000083-Ramp1">Ramp et al. 1997</xref>). Drugs directed against VEGF or its receptors are also being tested in humans (<xref ref-type="bibr" rid="pbio.0000083-Fabbro1">Fabbro et al. 2002</xref>). In a recent Phase II study, a neutralizing VEGF antibody was shown to delay disease progression in metastatic renal carcinoma (<xref ref-type="bibr" rid="pbio.0000083-Yang1">Yang et al. 2003</xref>) and offers hope that rational combinations of small molecules directed against HIF targets will alter the natural history of this disease.</p></sec></sec><sec sec-type="materials|methods" id="s3"><title>Materials and Methods</title><sec id="s3a"><title/><sec id="s3a1"><title>Plasmids</title><p>pBABE-puro-HA-HIF2&#x003b1; P405A;P531A was generated by two-step PCR. The pcDNA3.0-HA-HIF2&#x003b1; P531A (<xref ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>) insert was first amplified with primer A (5&#x02032;-GCGCGGATCCGCCACCATGACA-3&#x02032;) and primer B (5&#x02032;-TCCTGGGGTAGCAGCCAGCTG-3&#x02032;) or primer C (5&#x02032;-CAGCTGGCTGCTACCCCAGGA-3&#x02032;) and primer D (5&#x02032;-GCGCCAATTGTCAGGTGGCCTGGTC-3&#x02032;). Aliquots of these two PCRs were then mixed and amplified with primers A and D. The resulting PCR product was digested with BamHI and MunI and ligated into pBABE-puro-HA vector cut with BamHI and EcoRI. In parallel, similar reactions were carried out with pcDNA3.0-HA-HIF2&#x003b1; P531A/bHLH&#x0002a; (<xref ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>) as the PCR template to make pBABE-puro HA-HIF2&#x003b1; P405A;P531A;bHLH&#x0002a; (conversion of amino acids residues 24&#x02013;29, RCRRSK to ACAASA).</p><p>Short interfering RNAs (siRNAs) corresponding to two unique HIF2&#x003b1; 19mer sequences (#2, 5&#x02032;-GACAAGGTCTGCAAAGGGT-3&#x02032; and #3, 5&#x02032;-GGAGACGGAGGTGTTCTAT-3&#x02032;) downregulated HIF2&#x003b1; protein levels and HIF-dependent transcriptional activity. Synthetic oligonucleotides spanning the #2 siRNA sequence (5&#x02032;-GATCCCCGACAAGGTCTGCAAAGGGTTTCAAGAGAACCCTTTGCAGACCTTGTCTTTTTGGAAA-3&#x02032; and 5&#x02032;-AGCTTTTCCAAAAAGACAAGGTCTGCAAAGGGTTCTCTTGAAACCCTTTGCAGACCTTGTCGGG-3&#x02032;) or the #3 sequence (5&#x02032;-GATCCCCGGAGACGGAGGTGTTCTATTTCAAGAGAATAGAACACCTCCGTCTCCTTTTTGGAAA and 5&#x02032;-AGCTTTTCCAAAAAGGAGACGGAGGTGTTCTATTCTCTTGAAATAGAACACCTCCGTCTCCGGG-3&#x02032;) were annealed by incubation in 30 mM HEPES&#x02013;KOH (pH 7.4), 100 mM potassium acetate, 30 mM HEPES&#x02013;KOH, 2 mM Mg&#x02013;acetate for 4 min at 95&#x000b0;C followed by 10 min at 70&#x000b0;C. The resulting duplex oligonucleotides were phosphorylated with T4 polynucleotide kinase (Roche Molecular Biochemicals, Mannheim, Germany) according to the manufacturer's protocol and ligated into pRETRO-SUPER vector (<xref ref-type="bibr" rid="pbio.0000083-Brummelkamp1">Brummelkamp et al. 2002</xref>) cut with BglII and HindIII.</p><p>The pBABE-hygro-HA-HIF2&#x003b1; siRNA recognition site mutant for #3 siRNA (5&#x02032;-GGAGAC<bold>C</bold>GA<bold>A</bold>GT<bold>C</bold>TTCTAT-3&#x02032;) (called HIF2&#x003b1; MT) was generated by two-step PCR. The pcDNA3.0-HA-HIF2&#x003b1; insert was first amplified was first amplified with primer A and primer E (5&#x02032;-GTCTCCTTGCTCCGCCG-3&#x02032;) or primer F (5&#x02032;-CGAAGTCTTCTATGAGCTGGCCCATG-3&#x02032;) and primer D. Aliquots of these two PCRs were then mixed and amplified with primers A and D. The resulting PCR product was digested with BamHI and MunI and ligated into pBABE-hygro-HA vector cut with BamHI and EcoRI.</p><p>All plasmids were authenticated by DNA sequencing. pGL2-VEGF promoter plasmid was a kind gift from Dr. Deb Mukhopadhyay (Harvard Medical School, Boston, Massachusetts, United States). pSV-&#x003b2;-Gal plasmid was purchased from Promega Corporation (Madison, Wisconsin, United States).</p></sec><sec id="s3a2"><title>Cell culture</title><p>Renal carcinoma cell lines (786-O and A498) and Phoenix cells (a generous gift of Dr. Gary Nolan, Department of Molecular Pharmacology, Stanford University, Stanford, California, United States) were grown in Dulbecco's modified Eagle's medium containing 10&#x00025; fetal clone I (Hyclone, Logan Utah, United States) in presence of 10&#x00025; CO<sub>2</sub> at 37&#x000b0;C. 786-O renal cell carcinoma subclones stably transfected with either pRc/CMV empty vector (PRC3) or pRc/CMV-HA-VHL (WT8) (<xref ref-type="bibr" rid="pbio.0000083-Iliopoulos1">Iliopoulos et al. 1995</xref>) were grown in the same media supplemented with 1 mg/ml G418. Retrovirally infected cells were selected and maintained in the presence of puromycin (1.5 &#x003bc;g/ml for pBABE-puro retroviruses or 1.0 &#x003bc;g/ml for pSUPER retroviruses) or hygromycin 0.5 &#x003bc;g/ml for pBABE-hygro retrovirus.</p></sec><sec id="s3a3"><title>Retroviruses. </title><p>Retroviral plasmids were transfected into the Phoenix packaging cell line using FuGene (Roche Molecular Biochemicals) according to the manufacturer's instructions. Tissue culture supernatant was harvested 48 h later, passed though a 0.45-&#x003bc;m filter, and added to cells in the presence of 4 &#x003bc;g/ml polybrene.</p></sec><sec id="s3a4"><title>Immunoblot analysis</title><p>Cells were lysed in EBC lysis buffer (50 mM Tris &#x0005b;pH 8.0&#x0005d;, 120 mM NaCl, 0.5&#x00025; NP-40) supplemented with complete protease inhibitor cocktail (Roche Molecular Biochemicals). Approximately 300 &#x003bc;g of cell extract per lane, as determined by the Bradford method, was resolved by SDS&#x02013;polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, California, United States). After blocking in Tris-buffered saline (TBS) with 4&#x00025; nonfat milk, the membranes were probed with anti-HA rabbit polyclonal antibody (Y-11; Santa Cruz Biotechnology, Santa Cruz, California, United States), anti-HIF2&#x003b1; mouse monoclonal antibody (NB100&#x02013;132; Novus Biologicals, Littleton, Colorado, United States), anti-GLUT1 rabbit polyclonal antibody (GT11-A; Alpha Diagnostic, San Antonio, Texas, United States), or anti-actin goat polyclonal antibody (sc-1615; Santa Cruz Biotechnology) diluted in TBS with 4&#x00025; bovine serum albumin. Bound antibody was detected with horseradish peroxidase-conjugated goat anti-rabbit IgG, goat anti-mouse IgG, or rabbit anti-goat IgG (Pierce, Rockford, Illinois, United States) and SuperSignal West Pico chemiluminescent substrate (Pierce) according to the manufacturer's instructions.</p></sec><sec id="s3a5"><title>In vitro proliferation assays</title><p>Approximately 5,000 cells were plated per well in 6-well plates and grown under the cell culture conditions described above. At various timepoints thereafter, cells were released by trypsinization, resuspended in phosphate-buffered saline (PBS), and stained with trypan blue. Viable cells, as determined by trypan blue exclusion, were counted using a hemocytometer.</p></sec><sec id="s3a6"><title><italic>Nude</italic> mouse xenograft assays</title><p><italic>Nude</italic> mouse xenograft assays were performed as described elsewhere (<xref ref-type="bibr" rid="pbio.0000083-Iliopoulos1">Iliopoulos et al. 1995</xref>; <xref ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>). In brief, cells were released by trypsinization and resuspended in PBS. Viable cells (10<sup>7</sup>), as determined by trypan blue staining, were injected subcutaneously into the flanks of <italic>nude</italic> mice. Both flanks were used for each mouse. The animals were sacrificed 8&#x02013;10 wk after injection. Autopsy was performed by animal care technicians who were unaware of the HIF status of the tumors. Tumors were weighed, cut in half, and fixed in either formalin or frozen in optimal cutting temperature compound.</p></sec></sec></sec></body><back><ack><p>We thank members of the Kaelin Laboratory for useful discussions and Rene Bernards for generously providing the pSUPER-retro plasmid prior to publication. WGK is a Howard Hughes Medical Institute investigator. This work was sponsored by the National Cancer Institute and the Murray Foundation.</p></ack><ref-list><title>References</title><ref id="pbio.0000083-Ang1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ang</surname><given-names>SO</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Hirota</surname><given-names>K</given-names></name><name><surname>Gordeuk</surname><given-names>VR</given-names></name><name><surname>Jelinek</surname><given-names>J</given-names></name><etal/></person-group><article-title>Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia</article-title><source>Nat Genet</source><year>2002</year><volume>32</volume><fpage>614</fpage><lpage>621</lpage><pub-id pub-id-type="pmid">12415268</pub-id></citation></ref><ref id="pbio.0000083-Brown1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>L</given-names></name><name><surname>Berse</surname><given-names>B</given-names></name><name><surname>Jackman</surname><given-names>R</given-names></name><name><surname>Tognazzi</surname><given-names>K</given-names></name><name><surname>Manseau</surname><given-names>E</given-names></name><etal/></person-group><article-title>Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas</article-title><source>Am J Pathol</source><year>1993</year><volume>143</volume><fpage>1255</fpage><lpage>1262</lpage><pub-id pub-id-type="pmid">8238242</pub-id></citation></ref><ref id="pbio.0000083-Brummelkamp1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brummelkamp</surname><given-names>TR</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name><name><surname>Agami</surname><given-names>R</given-names></name></person-group><article-title>Stable suppression of tumorigenicity by virus-mediated RNA interference</article-title><source>Cancer Cell</source><year>2002</year><volume>2</volume><fpage>243</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">12242156</pub-id></citation></ref><ref id="pbio.0000083-Carmeliet1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carmeliet</surname><given-names>P</given-names></name><name><surname>Dor</surname><given-names>Y</given-names></name><name><surname>Herbert</surname><given-names>JM</given-names></name><name><surname>Fukumura</surname><given-names>D</given-names></name><name><surname>Brusselmans</surname><given-names>K</given-names></name><etal/></person-group><article-title>Role of HIF-1&#x003b1; in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis</article-title><source>Nature</source><year>1998</year><volume>394</volume><fpage>485</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">9697772</pub-id></citation></ref><ref id="pbio.0000083-Chailler1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chailler</surname><given-names>P</given-names></name><name><surname>Briere</surname><given-names>N</given-names></name></person-group><article-title>Mitogenic effects of EGF/TGF alpha and immunolocalization of cognate receptors in human fetal kidneys</article-title><source>Biofactors</source><year>1998</year><volume>7</volume><fpage>323</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">9666320</pub-id></citation></ref><ref id="pbio.0000083-Clifford1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clifford</surname><given-names>S</given-names></name><name><surname>Cockman</surname><given-names>M</given-names></name><name><surname>Smallwood</surname><given-names>A</given-names></name><name><surname>Mole</surname><given-names>D</given-names></name><name><surname>Woodward</surname><given-names>E</given-names></name><etal/></person-group><article-title>Contrasting effects on HIF-1&#x003b1; regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel&#x02013;Lindau disease</article-title><source>Hum Mol Genet</source><year>2001</year><volume>10</volume><fpage>1029</fpage><lpage>1038</lpage><pub-id pub-id-type="pmid">11331613</pub-id></citation></ref><ref id="pbio.0000083-Davidowitz1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davidowitz</surname><given-names>E</given-names></name><name><surname>Schoenfeld</surname><given-names>A</given-names></name><name><surname>Burk</surname><given-names>R</given-names></name></person-group><article-title>VHL induces renal cell differentiation and growth arrest through integration of cell&#x02013;cell and cell&#x02013;extracellular matrix signaling</article-title><source>Mol Cell Biol</source><year>2001</year><volume>21</volume><fpage>865</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">11154273</pub-id></citation></ref><ref id="pbio.0000083-de1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Paulsen</surname><given-names>N</given-names></name><name><surname>Brychzy</surname><given-names>A</given-names></name><name><surname>Fournier</surname><given-names>MC</given-names></name><name><surname>Klausner</surname><given-names>RD</given-names></name><name><surname>Gnarra</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Role of transforming growth factor-alpha in VHL<sup>&#x02212;/&#x02212;</sup> clear cell renal carcinoma cell proliferation: A possible mechanism coupling von Hippel&#x02013;Lindau tumor suppressor inactivation and tumorigenesis</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>1387</fpage><lpage>1392</lpage><pub-id pub-id-type="pmid">11171960</pub-id></citation></ref><ref id="pbio.0000083-Elson1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elson</surname><given-names>D</given-names></name><name><surname>Thurston</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Ginzinger</surname><given-names>D</given-names></name><name><surname>McDonald</surname><given-names>D</given-names></name><etal/></person-group><article-title>Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1&#x003b1;</article-title><source>Genes Dev</source><year>2001</year><volume>15</volume><fpage>2520</fpage><lpage>2532</lpage><pub-id pub-id-type="pmid">11581158</pub-id></citation></ref><ref id="pbio.0000083-Fabbro1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fabbro</surname><given-names>D</given-names></name><name><surname>Parkinson</surname><given-names>D</given-names></name><name><surname>Matter</surname><given-names>A</given-names></name></person-group><article-title>Protein tyrosine kinase inhibitors: New treatment modalities?</article-title><source>Curr Opin Pharmacol</source><year>2002</year><volume>2</volume><fpage>374</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">12127869</pub-id></citation></ref><ref id="pbio.0000083-Gnarra1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gnarra</surname><given-names>JR</given-names></name><name><surname>Tory</surname><given-names>K</given-names></name><name><surname>Weng</surname><given-names>Y</given-names></name><name><surname>Schmidt</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Mutations of the <italic>VHL</italic> tumour suppressor gene in renal carcinoma</article-title><source>Nat Genet</source><year>1994</year><volume>7</volume><fpage>85</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">7915601</pub-id></citation></ref><ref id="pbio.0000083-Gnarra2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gnarra</surname><given-names>JR</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Merrill</surname><given-names>MJ</given-names></name><name><surname>Wagner</surname><given-names>J</given-names></name><name><surname>Krumm</surname><given-names>A</given-names></name><etal/></person-group><article-title>Post-transcriptional regulation of vascular endothelial growth factor mRNA by the <italic>VHL</italic> tumor suppressor gene product</article-title><source>Proc Natl Acad Sci U S A</source><year>1996</year><volume>93</volume><fpage>10589</fpage><lpage>10594</lpage><pub-id pub-id-type="pmid">8855222</pub-id></citation></ref><ref id="pbio.0000083-Haase1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haase</surname><given-names>V</given-names></name><name><surname>Glickman</surname><given-names>J</given-names></name><name><surname>Socolovsky</surname><given-names>M</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name></person-group><article-title>Vascular tumors in livers with targeted inactivation of the von Hippel&#x02013;Lindau tumor suppressor</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>1583</fpage><lpage>1588</lpage><pub-id pub-id-type="pmid">11171994</pub-id></citation></ref><ref id="pbio.0000083-Hoffman1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>M</given-names></name><name><surname>Ohh</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Klco</surname><given-names>J</given-names></name><name><surname>Ivan</surname><given-names>M</given-names></name><etal/></person-group><article-title>von Hippel&#x02013;Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF</article-title><source>Hum Mol Genet</source><year>2001</year><volume>10</volume><fpage>1019</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">11331612</pub-id></citation></ref><ref id="pbio.0000083-Hopfl1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hopfl</surname><given-names>G</given-names></name><name><surname>Wenger</surname><given-names>RH</given-names></name><name><surname>Ziegler</surname><given-names>U</given-names></name><name><surname>Stallmach</surname><given-names>T</given-names></name><name><surname>Gardelle</surname><given-names>O</given-names></name><etal/></person-group><article-title>Rescue of hypoxia-inducible factor-1&#x003b1;-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>2962</fpage><lpage>2970</lpage><pub-id pub-id-type="pmid">12019179</pub-id></citation></ref><ref id="pbio.0000083-Iliopoulos1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iliopoulos</surname><given-names>O</given-names></name><name><surname>Kibel</surname><given-names>A</given-names></name><name><surname>Gray</surname><given-names>S</given-names></name><name><surname>Kaelin</surname><given-names>WG</given-names></name></person-group><article-title>Tumor suppression by the human von Hippel&#x02013;Lindau gene product</article-title><source>Nat Med</source><year>1995</year><volume>1</volume><fpage>822</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">7585187</pub-id></citation></ref><ref id="pbio.0000083-Iliopoulos2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iliopoulos</surname><given-names>O</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Levy</surname><given-names>AP</given-names></name><name><surname>Kaelin</surname><given-names>WG</given-names></name><name><surname>Goldberg</surname><given-names>MA</given-names></name></person-group><article-title>Negative regulation of hypoxia-inducible genes by the von Hippel&#x02013;Lindau protein</article-title><source>Proc Natl Acad Sci U S A</source><year>1996</year><volume>93</volume><fpage>10595</fpage><lpage>10599</lpage><pub-id pub-id-type="pmid">8855223</pub-id></citation></ref><ref id="pbio.0000083-Ivan1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ivan</surname><given-names>M</given-names></name><name><surname>Kondo</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Valiando</surname><given-names>J</given-names></name><etal/></person-group><article-title>HIF&#x003b1; targeted for VHL-mediated destruction by proline hydroxylation: Implications for O<sub>2</sub> sensing</article-title><source>Science</source><year>2001</year><volume>292</volume><fpage>464</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">11292862</pub-id></citation></ref><ref id="pbio.0000083-Jaakkola1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jaakkola</surname><given-names>P</given-names></name><name><surname>Mole</surname><given-names>D</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Wilson</surname><given-names>M</given-names></name><name><surname>Gielbert</surname><given-names>J</given-names></name><etal/></person-group><article-title>Targeting of HIF-alpha to the von Hippel&#x02013;Lindau ubiquitylation complex by O<sub>2</sub>-regulated prolyl hydroxylation</article-title><source>Science</source><year>2001</year><volume>292</volume><fpage>468</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">11292861</pub-id></citation></ref><ref id="pbio.0000083-Kaelin1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaelin</surname><given-names>WG</given-names></name></person-group><article-title>Molecular basis of the VHL hereditary cancer syndrome</article-title><source>Nat Rev Cancer</source><year>2002</year><volume>2</volume><fpage>673</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">12209156</pub-id></citation></ref><ref id="pbio.0000083-Knebelmann1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knebelmann</surname><given-names>B</given-names></name><name><surname>Ananth</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>H</given-names></name><name><surname>Sukhatme</surname><given-names>V</given-names></name></person-group><article-title>Transforming growth factor alpha is a target for the von Hippel&#x02013;Lindau tumor suppressor</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>226</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">9443397</pub-id></citation></ref><ref id="pbio.0000083-Kondo1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>K</given-names></name><name><surname>Klco</surname><given-names>J</given-names></name><name><surname>Nakamura</surname><given-names>E</given-names></name><name><surname>Lechpammer</surname><given-names>M</given-names></name><name><surname>Kaelin</surname><given-names>WG</given-names></name></person-group><article-title>Inhibition of HIF is necessary for tumor suppression by the von Hippel&#x02013;Lindau protein</article-title><source>Cancer Cell</source><year>2002</year><volume>1</volume><fpage>237</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">12086860</pub-id></citation></ref><ref id="pbio.0000083-Lager1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lager</surname><given-names>D</given-names></name><name><surname>Slagel</surname><given-names>D</given-names></name><name><surname>Palechek</surname><given-names>P</given-names></name></person-group><article-title>The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma</article-title><source>Mod Pathol</source><year>1994</year><volume>7</volume><fpage>544</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">7937720</pub-id></citation></ref><ref id="pbio.0000083-Lonergan1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lonergan</surname><given-names>KM</given-names></name><name><surname>Iliopoulos</surname><given-names>O</given-names></name><name><surname>Ohh</surname><given-names>M</given-names></name><name><surname>Kamura</surname><given-names>T</given-names></name><name><surname>Conaway</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Regulation of hypoxia-inducible mRNAs by the von Hippel&#x02013;Lindau protein requires binding to complexes containing elongins B/C and Cul2</article-title><source>Mol Cell Biol</source><year>1998</year><volume>18</volume><fpage>732</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">9447969</pub-id></citation></ref><ref id="pbio.0000083-Lowden1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lowden</surname><given-names>D</given-names></name><name><surname>Lindemann</surname><given-names>G</given-names></name><name><surname>Merlino</surname><given-names>G</given-names></name><name><surname>Barash</surname><given-names>B</given-names></name><name><surname>Calvet</surname><given-names>J</given-names></name><etal/></person-group><article-title>Renal cysts in transgenic mice expressing transforming growth factor-alpha</article-title><source>J Lab Clin Med</source><year>1994</year><volume>124</volume><fpage>386</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">8083581</pub-id></citation></ref><ref id="pbio.0000083-Lubensky1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lubensky</surname><given-names>IA</given-names></name><name><surname>Gnarra</surname><given-names>JR</given-names></name><name><surname>Bertheau</surname><given-names>P</given-names></name><name><surname>Walther</surname><given-names>MM</given-names></name><name><surname>Linehan</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel&#x02013;Lindau disease patients</article-title><source>Am J Pathol</source><year>1996</year><volume>149</volume><fpage>2089</fpage><lpage>2094</lpage><pub-id pub-id-type="pmid">8952541</pub-id></citation></ref><ref id="pbio.0000083-Mack1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mack</surname><given-names>FA</given-names></name><name><surname>Rathmell</surname><given-names>WK</given-names></name><name><surname>Arsham</surname><given-names>AM</given-names></name><name><surname>Gnarra</surname><given-names>J</given-names></name><name><surname>Keith</surname><given-names>B</given-names></name><etal/></person-group><article-title>Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth</article-title><source>Cancer Cell</source><year>2003</year><volume>3</volume><fpage>75</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">12559177</pub-id></citation></ref><ref id="pbio.0000083-Mandriota1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mandriota</surname><given-names>SJ</given-names></name><name><surname>Turner</surname><given-names>KJ</given-names></name><name><surname>Davies</surname><given-names>DR</given-names></name><name><surname>Murray</surname><given-names>PG</given-names></name><name><surname>Morgan</surname><given-names>NV</given-names></name><etal/></person-group><article-title>HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron</article-title><source>Cancer Cell</source><year>2002</year><volume>1</volume><fpage>459</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">12124175</pub-id></citation></ref><ref id="pbio.0000083-Masson1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Masson</surname><given-names>N</given-names></name><name><surname>Willam</surname><given-names>C</given-names></name><name><surname>Maxwell</surname><given-names>P</given-names></name><name><surname>Pugh</surname><given-names>C</given-names></name><name><surname>Ratcliffe</surname><given-names>P</given-names></name></person-group><article-title>Independent function of two destruction domains in hypoxia-inducible factor-&#x003b1; chains activated by prolyl hydroylation</article-title><source>EMBO J</source><year>2001</year><volume>20</volume><fpage>5197</fpage><lpage>5206</lpage><pub-id pub-id-type="pmid">11566883</pub-id></citation></ref><ref id="pbio.0000083-Maxwell1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maxwell</surname><given-names>P</given-names></name><name><surname>Dachs</surname><given-names>G</given-names></name><name><surname>Gleadle</surname><given-names>J</given-names></name><name><surname>Nicholls</surname><given-names>L</given-names></name><name><surname>Harris</surname><given-names>A</given-names></name><etal/></person-group><article-title>Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth</article-title><source>Proc Natl Acad Sci U S A</source><year>1997</year><volume>94</volume><fpage>8104</fpage><lpage>8109</lpage><pub-id pub-id-type="pmid">9223322</pub-id></citation></ref><ref id="pbio.0000083-Maxwell2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maxwell</surname><given-names>P</given-names></name><name><surname>Weisner</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>G-W</given-names></name><name><surname>Clifford</surname><given-names>S</given-names></name><name><surname>Vaux</surname><given-names>E</given-names></name><etal/></person-group><article-title>The von Hippel&#x02013;Lindau gene product is necessary for oxgyen-dependent proteolysis of hypoxia-inducible factor &#x003b1; subunits</article-title><source>Nature</source><year>1999</year><volume>399</volume><fpage>271</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">10353251</pub-id></citation></ref><ref id="pbio.0000083-Mydlo1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mydlo</surname><given-names>J</given-names></name><name><surname>Michaeli</surname><given-names>J</given-names></name><name><surname>Cordon-Cardo</surname><given-names>C</given-names></name><name><surname>Goldenberg</surname><given-names>A</given-names></name><name><surname>Heston</surname><given-names>W</given-names></name><etal/></person-group><article-title>Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and non-neoplastic human kidney tissue</article-title><source>Cancer Res</source><year>1989</year><volume>49</volume><fpage>3407</fpage><lpage>3411</lpage><pub-id pub-id-type="pmid">2720695</pub-id></citation></ref><ref id="pbio.0000083-Nicol1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nicol</surname><given-names>D</given-names></name><name><surname>Hii</surname><given-names>SI</given-names></name><name><surname>Walsh</surname><given-names>M</given-names></name><name><surname>Teh</surname><given-names>B</given-names></name><name><surname>Thompson</surname><given-names>L</given-names></name><etal/></person-group><article-title>Vascular endothelial growth factor expression is increased in renal cell carcinoma</article-title><source>J Urol</source><year>1997</year><volume>157</volume><fpage>1482</fpage><lpage>1486</lpage><pub-id pub-id-type="pmid">9120987</pub-id></citation></ref><ref id="pbio.0000083-Ramp1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramp</surname><given-names>U</given-names></name><name><surname>Jaquet</surname><given-names>K</given-names></name><name><surname>Reinecke</surname><given-names>P</given-names></name><name><surname>Schardt</surname><given-names>C</given-names></name><name><surname>Friebe</surname><given-names>U</given-names></name><etal/></person-group><article-title>Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type</article-title><source>J Urol</source><year>1997</year><volume>157</volume><fpage>2345</fpage><lpage>2350</lpage><pub-id pub-id-type="pmid">9146668</pub-id></citation></ref><ref id="pbio.0000083-Ramp2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramp</surname><given-names>U</given-names></name><name><surname>Reinecke</surname><given-names>P</given-names></name><name><surname>Gabbert</surname><given-names>H</given-names></name><name><surname>Gerharz</surname><given-names>C</given-names></name></person-group><article-title>Differential response to transforming growth factor (TGF)-alpha and fibroblast growth factor (FGF) in human renal cell carcinomas of the clear cell and papillary types</article-title><source>Eur J Cancer</source><year>2000</year><volume>36</volume><fpage>932</fpage><lpage>941</lpage><pub-id pub-id-type="pmid">10785600</pub-id></citation></ref><ref id="pbio.0000083-Rebar1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rebar</surname><given-names>EJ</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Hickey</surname><given-names>R</given-names></name><name><surname>Nath</surname><given-names>AK</given-names></name><name><surname>Meoli</surname><given-names>D</given-names></name><etal/></person-group><article-title>Induction of angiogenesis in a mouse model using engineered transcription factors</article-title><source>Nat Med</source><year>2002</year><volume>8</volume><fpage>1427</fpage><lpage>1432</lpage><pub-id pub-id-type="pmid">12415262</pub-id></citation></ref><ref id="pbio.0000083-Ryan1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>H</given-names></name><name><surname>Lo</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>R</given-names></name></person-group><article-title>HIF-1&#x003b1; is required for solid tumor formation and embryonic vascularization</article-title><source>EMBO J</source><year>1998</year><volume>17</volume><fpage>3005</fpage><lpage>3015</lpage><pub-id pub-id-type="pmid">9606183</pub-id></citation></ref><ref id="pbio.0000083-Ryan2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>H</given-names></name><name><surname>Poloni</surname><given-names>M</given-names></name><name><surname>McNulty</surname><given-names>W</given-names></name><name><surname>Elson</surname><given-names>D</given-names></name><name><surname>Gassmann</surname><given-names>M</given-names></name><etal/></person-group><article-title>Hypoxia-inducible factor-1&#x003b1; is a positive factor in solid tumor growth</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>4010</fpage><lpage>4015</lpage><pub-id pub-id-type="pmid">10945599</pub-id></citation></ref><ref id="pbio.0000083-Schoenfeld1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schoenfeld</surname><given-names>A</given-names></name><name><surname>Davidowitz</surname><given-names>E</given-names></name><name><surname>Burk</surname><given-names>R</given-names></name></person-group><article-title>A second major native von Hippel&#x02013;Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor</article-title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><fpage>8817</fpage><lpage>8822</lpage><pub-id pub-id-type="pmid">9671762</pub-id></citation></ref><ref id="pbio.0000083-Takahashi1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Tobisu</surname><given-names>K</given-names></name><name><surname>Kakizoe</surname><given-names>T</given-names></name><etal/></person-group><article-title>Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis</article-title><source>Cancer Res</source><year>1994</year><volume>54</volume><fpage>4233</fpage><lpage>4237</lpage><pub-id pub-id-type="pmid">7518352</pub-id></citation></ref><ref id="pbio.0000083-Takahashi2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Kahnoski</surname><given-names>R</given-names></name><name><surname>Gross</surname><given-names>D</given-names></name><name><surname>Nicol</surname><given-names>D</given-names></name><name><surname>Teh</surname><given-names>BT</given-names></name></person-group><article-title>Familial adult renal neoplasia</article-title><source>J Med Genet</source><year>2002</year><volume>39</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">11826016</pub-id></citation></ref><ref id="pbio.0000083-Vincent1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>K</given-names></name><name><surname>Shyu</surname><given-names>K</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Magner</surname><given-names>M</given-names></name><name><surname>Tio</surname><given-names>R</given-names></name><etal/></person-group><article-title>Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1&#x003b1;/VP16 hybrid transcription factor</article-title><source>Circulation</source><year>2000</year><volume>102</volume><fpage>2255</fpage><lpage>2261</lpage><pub-id pub-id-type="pmid">11056102</pub-id></citation></ref><ref id="pbio.0000083-Walke1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walke</surname><given-names>C</given-names></name><name><surname>Everitt</surname><given-names>J</given-names></name><name><surname>Freed</surname><given-names>J</given-names></name><name><surname>Knudson</surname><given-names>AJ</given-names></name><name><surname>Whiteley</surname><given-names>L</given-names></name></person-group><article-title>Altered expression of transforming growth factor-alpha in hereditary rat renal cell carcinoma</article-title><source>Cancer Res</source><year>1991</year><volume>51</volume><fpage>2973</fpage><lpage>2978</lpage><pub-id pub-id-type="pmid">2032234</pub-id></citation></ref><ref id="pbio.0000083-Yang1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Haworth</surname><given-names>L</given-names></name><name><surname>Sherry</surname><given-names>RM</given-names></name><name><surname>Hwu</surname><given-names>P</given-names></name><name><surname>Schwartzentruber</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><fpage>427</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">12890841</pub-id></citation></ref><ref id="pbio.0000083-Yu1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>White</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Lee</surname><given-names>F</given-names></name></person-group><article-title>HIF-1&#x003b1; binding to VHL is regulated by stimulus-sensitive proline hydroxylation</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>9630</fpage><lpage>9635</lpage><pub-id pub-id-type="pmid">11504942</pub-id></citation></ref><ref id="pbio.0000083-Zhuang1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>Z</given-names></name><name><surname>Bertheau</surname><given-names>P</given-names></name><name><surname>Emmert-Buck</surname><given-names>M</given-names></name><name><surname>Liotta</surname><given-names>L</given-names></name><name><surname>Gnarra</surname><given-names>J</given-names></name><etal/></person-group><article-title>A microscopic dissection technique for archival DNA analysis of specific cell populations in lesions &#x0003c;1 mm in size</article-title><source>Am J Pathol</source><year>1995</year><volume>146</volume><fpage>620</fpage><lpage>625</lpage><pub-id pub-id-type="pmid">7887444</pub-id></citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>bHLH</term><def><p>basic helix&#x02013;loop&#x02013;helix</p></def></def-item><def-item><term>EGF</term><def><p>epidermal growth factor</p></def></def-item><def-item><term>EGFR</term><def><p>epidermal growth factor receptor</p></def></def-item><def-item><term>EGLN</term><def><p>egg-laying-defective nine</p></def></def-item><def-item><term>GLUT1</term><def><p>glucose transporter 1</p></def></def-item><def-item><term>HIF</term><def><p>hypoxia-inducible factor</p></def></def-item><def-item><term>PBS</term><def><p>phosphate-buffered saline</p></def></def-item><def-item><term>pVHL</term><def><p><italic>VHL</italic> gene product</p></def></def-item><def-item><term>shRNA</term><def><p>short hairpin RNA</p></def></def-item><def-item><term>siRNA</term><def><p>short interfering RNA</p></def></def-item><def-item><term>TBS</term><def><p>Tris-buffered saline</p></def></def-item><def-item><term>TGF</term><def><p>transforming growth factor</p></def></def-item><def-item><term>VEGF</term><def><p>vascular endothelial growth factor</p></def></def-item><def-item><term>VHL</term><def><p>von Hippel&#x02013;Lindau</p></def></def-item></def-list></glossary><sec sec-type="display-objects"><title>Figures and Tables</title><fig id="pbio.0000083-g001" position="float"><label>Figure 1</label><caption><title>HIF2&#x003b1; Overrides Tumor Suppression by pVHL</title><p>(A) 786-O subclones that were transfected to produce wild-type pVHL (WT8) or with an empty plasmid (PRC3) cells, as well as WT8 cells infected with an empty retrovirus (Empty) or retroviruses encoding the indicated HIF2&#x003b1; variants &#x0005b; (P&#x02192;A)<sup>2</sup> &#x0003d; P405A;P531A and &#x0002a; &#x0003d; bHLH mutation&#x0005d; were grown in the presence of 21&#x00025; or 1&#x00025; oxygen and immunoblotted (IB) with the indicated antibodies.</p><p>(B) In vitro proliferation of WT8 cells infected with the indicated retroviruses.</p><p>(C) Tumor weights approximately 9 wk after subcutaneous implantation of WT8 cells infected with the indicated retroviruses in <italic>nude</italic> mice. Number of tumors analyzed is shown in parentheses. Error bars &#x0003d; one standard error.</p></caption><graphic xlink:href="pbio.0000083.g001"/></fig><fig id="pbio.0000083-g002" position="float"><label>Figure 2</label><caption><title>Downregulation of HIF2&#x003b1; Is Sufficient to Suppress Tumor Growth by pVHL-Defective Renal Carcinoma Cells</title><p>(A) Parental 786-O cells (<italic>VHL</italic>&#x0005b;&#x02212;/&#x02212;&#x0005d;) and 786-O cells infected with an empty retrovirus (Empty) or retroviruses encoding HIF2&#x003b1; shRNAs (sequence #2 or #3) were grown in the presence of 21&#x00025; or 1&#x00025; oxygen and immunoblotted (IB) with the indicated antibodies.</p><p>(B) In vitro proliferation of 786-O cells infected with the indicated retroviruses.</p><p>(C) Tumor weights approximately 9 wk after subcutaneous implantation of 786-O cells infected with the indicated retroviruses in <italic>nude</italic> mice. Number of tumors analyzed is shown in parentheses. Error bars &#x0003d; one standard error.</p><p>(D) Representative photograph of <italic>nude</italic> mouse 9 wk after subcutaneous injection of 786-O cells in left (upper) flank and 786-O cells infected with HIF2&#x003b1; shRNA (#3) retrovirus on right (lower) flank.</p></caption><graphic xlink:href="pbio.0000083.g002"/></fig><fig id="pbio.0000083-g003" position="float"><label>Figure 3</label><caption><title>Effect of HIF2&#x003b1; shRNA Is Specifically Due to Downregulation of HIF2&#x003b1;</title><p>(A) Parental 786-O cells (<italic>VHL</italic>&#x0005b;&#x02212;/&#x02212;&#x0005d;) and 786-O cells stably producing HIF2&#x003b1; shRNA #3 that were coinfected with an empty retrovirus (Empty) or a retrovirus encoding a HIF2&#x003b1; mRNA with three silent mutations in the #3 recognition site (MT&#x0002a;) were grown in the presence of 21&#x00025; or 1&#x00025; oxygen and immunoblotted (IB) with the indicated antibodies.</p><p>(B) In vitro proliferation of 786-O HIF2&#x003b1; shRNA #3 cells infected with the indicated retroviruses.</p><p>(C) Tumor weights approximately 9 wk after subcutaneous implantation of 786-O HIF2&#x003b1; shRNA cells infected with the indicated retroviruses in <italic>nude</italic> mice. Number of tumors analyzed is shown in parentheses. Error bars &#x0003d; one standard error.</p><p>(D) Representative photograph of <italic>nude</italic> mouse 9 wk after subcutaneous injection of 786-O HIF2&#x003b1; shRNA #3 cells in left (upper) flank and 786-O HIF2&#x003b1; shRNA #3 cells infected with retrovirus encoding HIF2&#x003b1; MT&#x0002a; mRNA on right (lower) flank.</p></caption><graphic xlink:href="pbio.0000083.g003"/></fig><fig id="pbio.0000083-g004" position="float"><label>Figure 4</label><caption><title>Tumor Suppression by HIF2&#x003b1; shRNA Is Not Restricted to a Single Cell Line</title><p>(A) Tumor weights approximately 8 wk after subcutaneous implantation of A498 cells infected with the indicated retroviruses in <italic>nude</italic> mice. Number of tumors analyzed is shown in parentheses. Error bars &#x0003d; one standard error.</p><p>(B) Representative histological sections after staining with hematoxylin and eosin of tumors formed by A498 cells infected with the indicated retroviruses.</p></caption><graphic xlink:href="pbio.0000083.g004"/></fig></sec><fn-group><fn id="n1" fn-type="conflict"><p><bold>Conflicts of interest.</bold> The authors have declared that no conflicts of interest exist.</p></fn><fn id="n2" fn-type="con"><p><bold>Author contributions.</bold> KK and WGK conceived and designed the experiments. KK, WYK, and ML performed the experiments. KK, ML, and WGK analyzed the data. KK contributed reagents/materials/analysis tools. WYK and WGK wrote the paper.</p></fn><fn id="n3" fn-type="edited-by"><p>Academic Editor: Christopher Kemp, Fred Hutchinson Cancer Research Center</p></fn></fn-group></back></article> 